The semaglutide cohort ( n = 25,686) compared with the non-GLP-1RA anti-obesity medications cohort ( n = 573,117) was younger, had a higher prevalence of problems related to lifestyle, severe obesity, obesity-associated comorbidities and mental disorders
Some people can get up to 80% off their prescription drug prices
Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial, The Lancet, 2025
It promotes long-term blood sugar control and significant weight loss without causing adverse effects on cardiovascular health or any other complications related to heart health or kidney function
Patients who participate in medical weight loss programs are able to move past the misconception that maintaining a healthy weight only requires self-control and a balanced diet
Even if you suspect the medication lost some potency, taking more than prescribed carries its own risks, particularly gastrointestinal side effects like constipation or increased burping